Keywords: positive, ph, iii, data, triangle, emtricitabine, 48-week
Positive Ph III data with Triangle's emtricitabine
Article | 17 February 2003
48-week results from an ongoing Phase III study of TrianglePharmaceuticals' nucleoside reverse transcriptase inhibitor emtricitabine have confirmed the ability of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
